Antifungal Drugs in Pulmonary Mucormycosis

Evaluation on Efficacy and Safety of Liposomal Amphotericin B(AmBisome® ) Combination with Isavuconazole Versus AmBisome® Alone for Treatment of Patients with Pulmonary Mucormycosis

Pulmonary mucormycosis (PM) poses a substantial clinical challenge, particularly among immunocompromised patients. The aim of the study is to determine the effectiveness and safety of administering AmBisome at a dose of 5mg/kg/day combined with isavuconazole versus using AmBisome for the management of pulmonary mucormycosis

Inclusion Criteria

• Patients aged 18 years or older diagnosed with pulmonary mucormycosis (PM).
• Individuals with Probable or proved PM, as indicated by clinical and radiological findings.

Exclusion Criteria:

• Patients with a history of pulmonary mucormycosis (PM) who have previously been treated with amphotericin B for a duration exceeding 5 days.
• Patients who have documented allergies to azoles or amphotericin B regimens
• Patients with serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase, or bilirubin levels exceeding five times the upper limit of normal (ULN).
• Patients with irreversible heart or liver failure, or those experiencing massive, fatal hemoptysis.
• Patients who have experienced a myocardial infarction or cerebral infarction.
• Patients currently receiving extracorporeal membrane oxygenation (ECMO) treatment.
• Pregnant or breastfeeding individuals. 8.Patients with individual reasons that may prevent them from completing the treatment protocol.